Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.

Pharmacogenomics - 1 Jan 2016

Huang Eric, Maciukiewicz Malgorzata, Zai Clement C, Tiwari Arun K, Li Jiang, Potkin Steven G, Lieberman Jeffrey A, Meltzer Herbert Y, Müller Daniel J, Kennedy James L

Abstract excerpt

AIM: The recent Psychiatric Genomics Consortium genome-wide association study identified an SNP, rs2514218, located 47kb upstream of the DRD2 gene to be associated with risk for schizophrenia (p = 2.75e-11). Since all antipsychotics bind to dopamine D2 receptors, we examined rs2514218 in relation to response to antipsychotic treatment. PATIENTS & METHODS: We investigated the SNP in relation to treatment response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antipsychotic Agents
Share to Clozapine
Share to DRD2 gene
Share to Genetic Association Studies
Share to Polymorphism, Single Nucleotide
Share to Receptors, Dopamine D2
Share to Risk
Share to Schizophrenia

Source

Identifiers

PMID: 26666695
DOI: 10.2217/pgs.15.155

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.PMID 26666695Read ↗

Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.Semantic proximity Read ↗

Treatment Response and GWAS Risk Allele rs2514218 (C) of the Dopamine D2 Receptor Gene in Inpatients with Schizophrenia.Semantic proximity Read ↗

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.Semantic proximity Read ↗

Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration.Semantic proximity Read ↗

Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response.Semantic proximity Read ↗

Meta-analysis of dopamine receptor D1 rs4532 polymorphism and susceptibility to antipsychotic treatment response.Semantic proximity Read ↗

Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes.Semantic proximity Read ↗

Recent Progress in Pharmacogenomics of Antipsychotic Drug Response.Semantic proximity Read ↗

The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.Semantic proximity Read ↗

Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.Semantic proximity Read ↗

Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.Semantic proximity Read ↗

DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.